Safety Profile (Phase 2) The most common adverse events were gastrointestinal and consistent with the incretin drug class: - Nausea - Diarrhea - Vomiting - Constipation - Decreased appetite These GI events were dose-related, mostly mild to moderate, and partially mitigated by starting at a lower initial dose (2 mg vs
If you are building a broader support plan, the Healthy-Aging collection is a useful place to explore related options
Specifications Research applications Analytical characterizationReceptor & molecular interactionIn vitro signalingComparative peptide research Store at 20 C
While these medications help some individuals, relapse rates remain stubbornly high, with approximately 70% of patients returning to problematic drinking within the first year of treatment
In the STEP TEENS trial, once-weekly semaglutide resulted in approximately 16% mean body weight reduction over 68 weeks, while liraglutide produced more modest reductions